Connecticut House Bill HB06097

Connecticut 2025 Regular Session

• Introduced: 1/22/25
• Refer: 1/22/25

Caption

An Act Concerning Prescription Drug Discount Transparency.

Impact

If enacted, HB 06097 would have significant implications for state laws governing prescription drug pricing and consumer rights. It aims to create a clearer view of drug pricing and reimbursement practices that could lead to increased scrutiny of how discounts are applied. By requiring formal reporting to the Office of Health Strategy, the bill looks to ensure that discounts are appropriately reflected in the costs borne by consumers, which would provide state regulators access to valuable data on pricing practices in the pharmaceutical market.

Summary

House Bill 06097, introduced by Representative Johnson, seeks to enhance transparency concerning prescription drug discounts. The bill mandates that pharmacy benefit managers, pharmacies, insurers, and hospitals that provide prescription drugs at discounted rates under Section 340B of the Public Health Service Act report the cost charged to consumers for these discounted drugs to the Office of Health Strategy. This initiative aims to guarantee that consumers are aware of the discounts available to them and not overpaying for prescription medications.

Contention

A notable point of contention surrounding HB 06097 includes concerns from various stakeholders regarding the feasibility and implications of additional reporting requirements. While supporters may argue that this measure is critical for consumer protection and ensuring fair pricing, opponents may express worries about the administrative burden that these requirements could impose on healthcare providers and the potential impact on the pricing dynamics within the pharmaceutical market. Ensuring compliance without stifling access to necessary medications is anticipated to be a critical area of debate as the bill progresses.